<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Leukemia</journal-id><journal-id journal-id-type="iso-abbrev">Leukemia</journal-id><journal-title-group><journal-title>Leukemia</journal-title></journal-title-group><issn pub-type="ppub">0887-6924</issn><issn pub-type="epub">1476-5551</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">37704711</article-id><article-id pub-id-type="pmc">PMC10624632</article-id>
<article-id pub-id-type="publisher-id">2026</article-id><article-id pub-id-type="doi">10.1038/s41375-023-02026-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Have we been qualifying measurable residual disease correctly?</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Feng</surname><given-names>Yahui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Qi</surname><given-names>Saibing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Xueou</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Qiujin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Xiaowen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Junxia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Tiantian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Huijun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Zhen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2572-6495</contrib-id><name><surname>Zhu</surname><given-names>Xiaofan</given-names></name><address><email>xfzhu@ihcams.ac.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9156-1676</contrib-id><name><surname>Gale</surname><given-names>Robert Peter</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3691-4931</contrib-id><name><surname>Chen</surname><given-names>Junren</given-names></name><address><email>chenjunren@ihcams.ac.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.461843.c</institution-id><institution>State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &#x00026; Blood Diseases Hospital, Chinese Academy of Medical Sciences &#x00026; Peking Union Medical College, </institution></institution-wrap>Tianjin, China </aff><aff id="Aff2"><label>2</label>Tianjin Institutes of Health Science, Tianjin, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041kmwe10</institution-id><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution>Centre for Haematology, Department of Immunology and Inflammation, </institution><institution>Imperial College of Science, Technology and Medicine, </institution></institution-wrap>London, UK </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>37</volume><issue>11</issue><fpage>2168</fpage><lpage>2172</lpage><history><date date-type="received"><day>21</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>30</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>5</day><month>9</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Acute lymphocytic leukaemia</kwd><kwd>Paediatrics</kwd></kwd-group><funding-group><award-group><funding-source><institution>the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-001 and 2022-I2M-2-003)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002855</institution-id><institution>Ministry of Science and Technology of the People&#x00026;apos;s Republic of China (Chinese Ministry of Science and Technology)</institution></institution-wrap></funding-source><award-id>2019YFA0110803</award-id><award-id>84000-51200002</award-id><principal-award-recipient><name><surname>Zhu</surname><given-names>Xiaofan</given-names></name><name><surname>Gale</surname><given-names>Robert Peter</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000272</institution-id><institution>DH | National Institute for Health Research (NIHR)</institution></institution-wrap></funding-source><award-id>Not applicable</award-id><principal-award-recipient><name><surname>Gale</surname><given-names>Robert Peter</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Ministry of Science and Technology of the People&#x00026;apos;s Republic of China (Chinese Ministry of Science and Technology)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par1">
<disp-quote><p id="Par2"><italic>Someone told me that each equation I included in the book would halve the sales. I therefore resolved not to have any equations at all. In the end, however, I did put in one equation, Einstein&#x02019;s famous equation, E = m c squared. I hope that this will not scare off half of my potential readers</italic>.</p><p id="Par3">Stephen Hawking</p></disp-quote>
</p><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par4">There is considerable interest in tests quantifying remaining leukaemia cells after therapy, termed measurable residual disease (MRD)-tests, to predict therapy outcomes, leukaemia recurrence and consider potential subsequent interventions [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Many studies reported a negative MRD-test during or after completing anti-leukaemia therapy independently identifies persons with a low risk of leukaemia relapse compared with those with a positive MRD-test after adjusting for other predictive and prognostic co-variates [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Other studies recommend specific interventions in someone with a positive MRD-test such as a haematopoietic cell transplant or immune therapy such as chimaeric antigen receptor (CAR)-T-cells. Whether such interventions reduce leukaemia relapse risk in someone with a positive MRD-test can only be proved in a randomized controlled trial [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par5">Most MRD-tests focus on detecting a leukaemia-related or -specific immune phenotype, cytogenetic and/or molecular abnormality [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. A perfect MRD-test would precisely quantify only leukaemia cells biologically capable of causing leukaemia relapse and likely to do so within a defined interval after accounting for competing causes of therapy-failure [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Routine clinical use of MRD-testing requires refinements and standardization/harmonization of assay platforms and result reporting [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par6">There is consensus a flow cytometry-based MRD-test should be reproducible at a limit of detection (LoD) of &#x02264;0.01% leukaemia cells in a blood or bone marrow sample [<xref ref-type="bibr" rid="CR26">26</xref>]. Based on this reasoning it is proposed a multi-parameter flow cytometry (MPFC)-based MRD-test should only be declared positive if &#x02265; <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$5\times 10{{\mbox{E+5}}}$$\end{document}</tex-math><mml:math id="M2"><mml:mn>5</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mn>10</mml:mn><mml:mstyle><mml:mtext>E+5</mml:mtext></mml:mstyle></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq1.gif"/></alternatives></inline-formula> cells are analysed and if &#x02265;20 or &#x02265;50 cells are positive [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. However, this definition is often unmet in clinical practice. For example, modern MRD-directed, risk-stratified approach to treating childhood acute lymphoblastic leukaemia (ALL) requires an MPFC-based MRD-test done in bone marrow aspirate&#x000a0;2&#x02013;3 weeks after starting induction chemotherapy, a time when collecting &#x0003e; <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$5\times 10{{\mbox{E+5}}}$$\end{document}</tex-math><mml:math id="M4"><mml:mn>5</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mn>10</mml:mn><mml:mstyle><mml:mtext>E+5</mml:mtext></mml:mstyle></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq2.gif"/></alternatives></inline-formula> bone marrow mononuclear cells is difficult [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The same limitation operates in adults receiving intensive induction chemotherapy. How should a physician use results of MRD-testing in these settings?</p></sec><sec id="Sec2"><title>Tyranny of sampling error</title><p id="Par7">Assume in an MPFC-based MRD-test <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N$$\end{document}</tex-math><mml:math id="M6"><mml:mi>N</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq3.gif"/></alternatives></inline-formula> cells are analysed out of which <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$n$$\end{document}</tex-math><mml:math id="M8"><mml:mi>n</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq4.gif"/></alternatives></inline-formula> cells are identified as <italic>leukaemia cells</italic>. By <italic>leukaemia cells</italic> we mean cells with immune phenotype of the leukaemia, not necessarily cells able to cause relapse within a defined interval. The conventional way to estimate MRD is <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}=\frac{n}{N}$$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq5.gif"/></alternatives></inline-formula> [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par8">When the true proportion of leukaemia cells (&#x0201c;true MRD&#x0201d;) is &#x0003c; <inline-formula id="IEq6"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{1}{N}$$\end{document}</tex-math><mml:math id="M12"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq6.gif"/></alternatives></inline-formula>, the standard error of <inline-formula id="IEq7"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M14"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq7.gif"/></alternatives></inline-formula> has a magnitude even larger than true MRD because of sampling error (Supplementary Methods). Simply put, the <inline-formula id="IEq8"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M16"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq8.gif"/></alternatives></inline-formula> test can be very imprecise.</p><p id="Par9">To better appreciate the tyranny of sampling error consider the hypothetical example of a haematologist reviewing the following MRD-test result: <inline-formula id="IEq9"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N=50000$$\end{document}</tex-math><mml:math id="M18"><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>50000</mml:mn></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq9.gif"/></alternatives></inline-formula> and <inline-formula id="IEq10"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$n=0$$\end{document}</tex-math><mml:math id="M20"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq10.gif"/></alternatives></inline-formula>. Analysing these few cells is not uncommon in practice for reasons we discussed above. Using the conventional approach to quantifying MRD the haematologist interprets this MRD-test as <inline-formula id="IEq11"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}=\frac{0}{50000}=0 \% .$$\end{document}</tex-math><mml:math id="M22"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>50000</mml:mn></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mi>%</mml:mi><mml:mo>.</mml:mo></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq11.gif"/></alternatives></inline-formula>&#x000a0;In doing so the haematologist fails to appreciate the result of this MRD-test is compatible with a broad range of true MRD values. In reality, the haematologist can only conclude MRD-test result is <inline-formula id="IEq12"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\le\!\!0.006 \%$$\end{document}</tex-math><mml:math id="M24"><mml:mo>&#x02264;</mml:mo><mml:mspace width="0.3em"/><mml:mspace width="0.3em"/><mml:mn>0.006</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq12.gif"/></alternatives></inline-formula> with a 5-percent probability true MRD is actually <inline-formula id="IEq13"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ &#x0003e; 0.006 \%$$\end{document}</tex-math><mml:math id="M26"><mml:mo>&#x0003e;</mml:mo><mml:mn>0.006</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq13.gif"/></alternatives></inline-formula>.</p><p id="Par10">Using Bayesian reasoning, the worst-case (probability &#x0003c;0.05)<xref ref-type="fn" rid="Fn1">1</xref> scenario estimate of MRD, which we denote as <inline-formula id="IEq15"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M28"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq15.gif"/></alternatives></inline-formula>, can be computed using a beta distribution (the formula is &#x0201c;BETA.INV (0.95, <inline-formula id="IEq16"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$1+n$$\end{document}</tex-math><mml:math id="M30"><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>n</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq16.gif"/></alternatives></inline-formula>, <inline-formula id="IEq17"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$1+N-n$$\end{document}</tex-math><mml:math id="M32"><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>n</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq17.gif"/></alternatives></inline-formula>)&#x0201d; in Microsoft Excel; Supplementary Methods) [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par12">Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> displays the extent to which <inline-formula id="IEq18"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M34"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq18.gif"/></alternatives></inline-formula> under-estimates true MRD at different values of <inline-formula id="IEq19"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N$$\end{document}</tex-math><mml:math id="M36"><mml:mi>N</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq19.gif"/></alternatives></inline-formula> in the worst-case scenario (that is, by how much <inline-formula id="IEq20"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M38"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq20.gif"/></alternatives></inline-formula> under-estimates <inline-formula id="IEq21"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M40"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq21.gif"/></alternatives></inline-formula>). Note that when <inline-formula id="IEq22"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M42"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq22.gif"/></alternatives></inline-formula> is <inline-formula id="IEq23"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\le 0.01 \%$$\end{document}</tex-math><mml:math id="M44"><mml:mo>&#x02264;</mml:mo><mml:mn>0.01</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq23.gif"/></alternatives></inline-formula>
<inline-formula id="IEq24"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M46"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq24.gif"/></alternatives></inline-formula> is considerably larger than <inline-formula id="IEq25"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M48"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq25.gif"/></alternatives></inline-formula> across a broad range of <inline-formula id="IEq26"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N$$\end{document}</tex-math><mml:math id="M50"><mml:mi>N</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq26.gif"/></alternatives></inline-formula> values. Conversely, when <inline-formula id="IEq27"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M52"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq27.gif"/></alternatives></inline-formula> is <inline-formula id="IEq28"><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\ge 0.1 \%$$\end{document}</tex-math><mml:math id="M54"><mml:mo>&#x02265;</mml:mo><mml:mn>0.1</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq28.gif"/></alternatives></inline-formula>
<inline-formula id="IEq29"><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M56"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq29.gif"/></alternatives></inline-formula> is usually very close to <inline-formula id="IEq30"><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M58"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq30.gif"/></alternatives></inline-formula> unless the number of analysed cells <italic>N</italic> is &#x0003c; 10E+5.<table-wrap id="Tab1"><label>Table 1</label><caption><p>To what extent <inline-formula id="IEq31"><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M60"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq31.gif"/></alternatives></inline-formula> under-estimates true MRD at different numbers of analysed cells <italic>N</italic> in the worst-case scenario.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th colspan="5">MRD<sub>conventional</sub></th></tr><tr><th/><th/><th>10%</th><th>1%</th><th>0.1%</th><th>0.01%</th><th>0.002%</th></tr></thead><tbody><tr><td rowspan="11"><italic>N</italic></td><td>50000</td><td>&#x02212;2%</td><td>&#x02212;7%</td><td>&#x02212;21%</td><td>&#x02212;52%</td><td>&#x02212;79%</td></tr><tr><td>100000</td><td>&#x02212;2%</td><td>&#x02212;5%</td><td>&#x02212;15%</td><td>&#x02212;41%</td><td>&#x02212;68%</td></tr><tr><td>200000</td><td>&#x02212;1%</td><td>&#x02212;4%</td><td>&#x02212;11%</td><td>&#x02212;31%</td><td>&#x02212;56%</td></tr><tr><td>300000</td><td>&#x02212;1%</td><td>&#x02212;3%</td><td>&#x02212;9%</td><td>&#x02212;26%</td><td>&#x02212;49%</td></tr><tr><td>400000</td><td>&#x02212;1%</td><td>&#x02212;3%</td><td>&#x02212;8%</td><td>&#x02212;23%</td><td>&#x02212;45%</td></tr><tr><td>500000</td><td>&#x02212;1%</td><td>&#x02212;2%</td><td>&#x02212;7%</td><td>&#x02212;21%</td><td>&#x02212;41%</td></tr><tr><td>600000</td><td>&#x02212;1%</td><td>&#x02212;2%</td><td>&#x02212;7%</td><td>&#x02212;19%</td><td>&#x02212;38%</td></tr><tr><td>700000</td><td>&#x02212;1%</td><td>&#x02212;2%</td><td>&#x02212;6%</td><td>&#x02212;18%</td><td>&#x02212;36%</td></tr><tr><td>800000</td><td>&#x02212;1%</td><td>&#x02212;2%</td><td>&#x02212;6%</td><td>&#x02212;17%</td><td>&#x02212;34%</td></tr><tr><td>900000</td><td>&#x02212;1%</td><td>&#x02212;2%</td><td>&#x02212;5%</td><td>&#x02212;16%</td><td>&#x02212;33%</td></tr><tr><td>1000000</td><td>0%</td><td>&#x02212;2%</td><td>&#x02212;5%</td><td>&#x02212;15%</td><td>&#x02212;31%</td></tr></tbody></table></table-wrap></p><p id="Par13">Typically result of an MRD-test is interpreted as positive or negative based on applying a cut-off threshold to <inline-formula id="IEq031"><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M62"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq031.gif"/></alternatives></inline-formula>. Our analysis of the adverse impact of sampling error (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) suggests any cut-off threshold &#x0003c;0.01% used in <inline-formula id="IEq32"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M64"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq32.gif"/></alternatives></inline-formula> would yield unreliable results with many false-negatives. Moreover, when estimating the hazard function of <inline-formula id="IEq33"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M66"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq33.gif"/></alternatives></inline-formula> for leukaemia relapse risk false-negatives would cause &#x0201c;flattening&#x0201d; of the estimated curve because the contrast between MRD-positives and -negatives is attenuated by contamination of false-negative MRD-test results.</p></sec><sec id="Sec3"><title>Borrowing lessons from decision science</title><p id="Par14">How to solve this problem when an inaccurate false-negative test result could have adverse clinical consequences? We propose the haematologist should instead rely on <inline-formula id="IEq34"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M68"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq34.gif"/></alternatives></inline-formula> rather than <inline-formula id="IEq35"><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M70"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq35.gif"/></alternatives></inline-formula> to estimate relapse risk.</p><p id="Par15">Our reasoning follows. When interpreting an MRD-test result to predict relapse the haematologist is essentially playing a &#x0201c;chess game against <italic>nature</italic>&#x0201d;. It&#x02019;s his/her 1st move to make, declaring the MRD-test result positive or negative. In response the opponent (<italic>nature</italic>) has two possible moves, causing relapse or not. When <inline-formula id="IEq36"><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M72"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq36.gif"/></alternatives></inline-formula> is larger the haematologist is more likely to later regret if he/she declares the MRD-test result negative, because more plausibly <italic>nature</italic> would <italic>play tricks</italic> on the haematologist by causing relapse.</p><p id="Par16">Ranking of people&#x02019;s test results based on <inline-formula id="IEq37"><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M74"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq37.gif"/></alternatives></inline-formula> from high to low values minimises the sum of regrets in the worst-case scenario because people whose MRD-test results are more likely to cause regret in case of a negative interpretation are already considered to have a higher risk of relapse. In the language of decision science, <inline-formula id="IEq38"><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M76"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq38.gif"/></alternatives></inline-formula> is a <italic>minimax regret</italic> approach to quantifying MRD test results according to Leonard Savage&#x02019;s theory of statistical decision or Herbert Simon&#x02019;s theory of rational choice under uncertainty [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec4"><title>A clinical example</title><p id="Par17">To illustrate using <inline-formula id="IEq39"><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M78"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq39.gif"/></alternatives></inline-formula> to interpret test results we interrogated data from 883 consecutive children with ALL &#x0003c;16 years (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>; Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>; and Supplementary Methods). The subjects were treated on the Chinese Children&#x02019;s Cancer Group study ALL-2015 (CCCG-ALL-2015) protocol [<xref ref-type="bibr" rid="CR32">32</xref>]. 618 (70%) and 265 (30%) of the children were low- and intermediate-risk at diagnosis according to the CCCG-ALL-2015 criteria. MPFC-based MRD-testing was done on bone marrow samples&#x000a0;19 days after starting therapy. Median number of analysed cells (<inline-formula id="IEq40"><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N$$\end{document}</tex-math><mml:math id="M80"><mml:mi>N</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq40.gif"/></alternatives></inline-formula>) was 4&#x02009;&#x000d7;&#x02009;10E+5 (Interquartile Range [IQR], 2.4&#x02013;5.0&#x02009;&#x000d7;&#x02009;10E+5; Range, 3.4&#x02009;&#x000d7;&#x02009;10E+3 to 1.0&#x02009;&#x000d7;&#x02009;10E+6). 686 (78%) MRD-tests analysed &#x0003c;5&#x02009;&#x000d7;&#x02009;10E+5 cells, a threshold stipulated by guideline for good laboratory practice (GLP) [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par18">294 (33%) children had <inline-formula id="IEq41"><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}} &#x0003c; 0.01 \%$$\end{document}</tex-math><mml:math id="M82"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mn>0.01</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq41.gif"/></alternatives></inline-formula> on day 19, 274 (93%) of whom had zero values (<italic>i.e</italic>. no leukaemia cell was detected [<inline-formula id="IEq42"><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$n=0$$\end{document}</tex-math><mml:math id="M84"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq42.gif"/></alternatives></inline-formula>]). The remainder (20 [7%]) had 8&#x02013;24 leukaemia cells detected. Because most children with <inline-formula id="IEq43"><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}} &#x0003c; 0.01 \%$$\end{document}</tex-math><mml:math id="M86"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mn>0.01</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq43.gif"/></alternatives></inline-formula> had no leukaemia cells detected in the sample, <inline-formula id="IEq44"><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M88"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq44.gif"/></alternatives></inline-formula> could not identify relative relapse risk in these children. The C-statistic (the probability of pairwise agreement with relapse time [<xref ref-type="bibr" rid="CR38">38</xref>]) of <inline-formula id="IEq45"><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M90"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq45.gif"/></alternatives></inline-formula> (0.57) was significantly higher (<italic>P</italic> &#x0003c;0.001; 2-sided Wilcoxon test on 500 bootstrap samples [<xref ref-type="bibr" rid="CR39">39</xref>]) compared with C-statistic of <inline-formula id="IEq46"><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M92"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq46.gif"/></alternatives></inline-formula> (0.50). In short, <inline-formula id="IEq47"><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M94"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq47.gif"/></alternatives></inline-formula> was a better predictor of relapse than <inline-formula id="IEq48"><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M96"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq48.gif"/></alternatives></inline-formula> when <inline-formula id="IEq49"><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M98"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq49.gif"/></alternatives></inline-formula> was close to zero (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1A</xref>). In contrast, for the 589 (67%) children who had <inline-formula id="IEq50"><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}\ge 0.01 \%$$\end{document}</tex-math><mml:math id="M100"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02265;</mml:mo><mml:mn>0.01</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq50.gif"/></alternatives></inline-formula> on day 19, C-statistics of <inline-formula id="IEq51"><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M102"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq51.gif"/></alternatives></inline-formula> (0.58) and <inline-formula id="IEq52"><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M104"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq52.gif"/></alternatives></inline-formula> (0.58) were similar (<italic>P</italic>&#x02009;=&#x02009;0.61).<fig id="Fig1"><label>Fig. 1</label><caption><title>Using MRD<sub>worse_case</sub> in a cohort of children with ALL.</title><p><bold>A</bold> Risk-stratifications based on <inline-formula id="IEq54"><alternatives><tex-math id="M105">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M106"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq54.gif"/></alternatives></inline-formula> vs. <inline-formula id="IEq55"><alternatives><tex-math id="M107">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M108"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq55.gif"/></alternatives></inline-formula> on day 19 when <inline-formula id="IEq56"><alternatives><tex-math id="M109">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}} &#x0003c; 0.01 \%$$\end{document}</tex-math><mml:math id="M110"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mn>0.01</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq56.gif"/></alternatives></inline-formula>. Cut-off threshold for distinguishing &#x0201c;<inline-formula id="IEq57"><alternatives><tex-math id="M111">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M112"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq57.gif"/></alternatives></inline-formula> high&#x0201d; and &#x0201c;<inline-formula id="IEq58"><alternatives><tex-math id="M113">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M114"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq58.gif"/></alternatives></inline-formula> low&#x0201d; is 7.3&#x02009;&#x000d7;&#x02009;10E&#x02212;6 or 0.00073%. <bold>B</bold> Hazard functions of <inline-formula id="IEq59"><alternatives><tex-math id="M115">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M116"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq59.gif"/></alternatives></inline-formula> and <inline-formula id="IEq60"><alternatives><tex-math id="M117">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M118"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq60.gif"/></alternatives></inline-formula> on day 19 for relapse risk. Curve estimation is based on data from the entire cohort of 883 children. Dotted lines indicate 95-percent confidence intervals. <bold>C</bold> Risk-stratification based on joint consideration of estimated relapse risk at diagnosis and <inline-formula id="IEq61"><alternatives><tex-math id="M119">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M120"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq61.gif"/></alternatives></inline-formula> on day 19 when <inline-formula id="IEq62"><alternatives><tex-math id="M121">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}} &#x0003c; 0.01 \%$$\end{document}</tex-math><mml:math id="M122"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mn>0.01</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq62.gif"/></alternatives></inline-formula>. Hazard ratios (HRs) and <italic>P</italic>-values are based on the Fine-Gray and Gray methods [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>].</p></caption><graphic xlink:href="41375_2023_2026_Fig1_HTML" id="d32e1619"/></fig></p><p id="Par19">We estimated non-linear hazard functions of <inline-formula id="IEq53"><alternatives><tex-math id="M123">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M124"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq53.gif"/></alternatives></inline-formula> and <inline-formula id="IEq054"><alternatives><tex-math id="M125">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M126"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq054.gif"/></alternatives></inline-formula> for relapse by fitting restricted cubic spline curves using Markov chain Monte Carlo [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. Since <inline-formula id="IEq055"><alternatives><tex-math id="M127">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M128"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq055.gif"/></alternatives></inline-formula> is always larger than <inline-formula id="IEq056"><alternatives><tex-math id="M129">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M130"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq056.gif"/></alternatives></inline-formula>, all else being equal, switching from <inline-formula id="IEq057"><alternatives><tex-math id="M131">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M132"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq057.gif"/></alternatives></inline-formula> to <inline-formula id="IEq058"><alternatives><tex-math id="M133">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M134"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq058.gif"/></alternatives></inline-formula> should induce a <italic>right-shift</italic> of the hazard function curve. Instead, we observed the hazard function of <inline-formula id="IEq059"><alternatives><tex-math id="M135">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M136"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq059.gif"/></alternatives></inline-formula> rose more steeply than the hazard function of <inline-formula id="IEq060"><alternatives><tex-math id="M137">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M138"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq060.gif"/></alternatives></inline-formula> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1B</xref>). Inaccuracies in MRD-estimation using the conventional approach distorted the critical range of MRD for discriminating low- from high-risks of cumulative incidence of relapse (CIR).</p><p id="Par20">Combining <inline-formula id="IEq061"><alternatives><tex-math id="M139">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M140"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq061.gif"/></alternatives></inline-formula> on day 19 with estimated relapse risk at diagnosis further improved risk-stratification of the children whose <inline-formula id="IEq062"><alternatives><tex-math id="M141">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M142"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq062.gif"/></alternatives></inline-formula> on day 19 was <inline-formula id="IEq63"><alternatives><tex-math id="M143">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ &#x0003c; 0.01 \%$$\end{document}</tex-math><mml:math id="M144"><mml:mo>&#x0003c;</mml:mo><mml:mn>0.01</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq63.gif"/></alternatives></inline-formula> with a C-statistic of 0.73. This was significantly better than using <inline-formula id="IEq64"><alternatives><tex-math id="M145">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M146"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq64.gif"/></alternatives></inline-formula> alone (0.73 vs. 0.57 [<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; 2-sided Wilcoxon test on 500 bootstrap samples]) or using relapse risk at diagnosis alone (0.73 vs. 0.68 [<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001]; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1C</xref>). 214 children (73%) with <inline-formula id="IEq65"><alternatives><tex-math id="M147">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}} &#x0003c; 0.01 \%$$\end{document}</tex-math><mml:math id="M148"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mn>0.01</mml:mn><mml:mi>%</mml:mi></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq65.gif"/></alternatives></inline-formula> on day 19 were low-risk at diagnosis and all subsequently received low-intensity therapy. The remainder (80 [27%]) were intermediate-risk at diagnosis and all received high-intensity therapy. Consequently, therapy-intensity did not confound results within each therapy cohort.</p><p id="Par21">Interestingly, point-estimates for relapse at 1.5 years for high- and low-<inline-formula id="IEq66"><alternatives><tex-math id="M149">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M150"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq66.gif"/></alternatives></inline-formula> cohorts were similar and their relapse curves only diverged after 1.5 years (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1A, C</xref>). Because <inline-formula id="IEq67"><alternatives><tex-math id="M151">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M152"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq67.gif"/></alternatives></inline-formula> corrected for (probable) under-sampling of leukaemia cells at therapy start this divergence likely resulted from expansion of pre-existing sub-clones during and/or after the end of low-intensity maintenance therapy (54 to 125 weeks) [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec5"><title>Is MRD<sub>worst_case</sub> an <italic>index</italic> or a <italic>metric</italic> for MRD?</title><p id="Par22"><italic>Index</italic> is defined as <italic>a number (such as a ratio) derived from a series of observations and used as an indicator or measure</italic>. <italic>Metric</italic> is defined as <italic>a standard of measurement</italic>. Some may argue <inline-formula id="IEq68"><alternatives><tex-math id="M153">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M154"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq68.gif"/></alternatives></inline-formula> is an <italic>index</italic> for MRD whilst <inline-formula id="IEq69"><alternatives><tex-math id="M155">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}=\frac{n}{N}$$\end{document}</tex-math><mml:math id="M156"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq69.gif"/></alternatives></inline-formula> is a <italic>metric</italic>. The distinction between <italic>index</italic> and <italic>metric</italic> is in some measure semantic. Even <inline-formula id="IEq70"><alternatives><tex-math id="M157">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M158"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq70.gif"/></alternatives></inline-formula> is a statistical construct for estimating likelihood of relapse. <inline-formula id="IEq71"><alternatives><tex-math id="M159">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M160"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq71.gif"/></alternatives></inline-formula> is what statisticians call a maximum-likelihood estimate, which is <italic>not</italic> the same as an estimate for the median <italic>(i.e</italic>. 50th-percentile) value among all the possible values of true MRD conditional on test result (Supplementary Methods). When <inline-formula id="IEq72"><alternatives><tex-math id="M161">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M162"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq72.gif"/></alternatives></inline-formula> is zero <inline-formula id="IEq73"><alternatives><tex-math id="M163">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M164"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq73.gif"/></alternatives></inline-formula> is actually the 0th-percentile (<italic>i.e</italic>. the lowest possible) value among all the possible values of true MRD conditional on test result! <inline-formula id="IEq74"><alternatives><tex-math id="M165">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M166"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq74.gif"/></alternatives></inline-formula>, on the other hand, is the 95th-percentile value among all the possible values of true MRD conditional on test result.</p></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p id="Par23">In this Perspective we argue the consensus GLP of MRD-testing is sub-optimal in many instances. Under these circumstances <inline-formula id="IEq75"><alternatives><tex-math id="M167">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M168"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq75.gif"/></alternatives></inline-formula> test results are sometimes mis-leading. Our analyses of data from a large cohort of childhood ALL indicates the <italic>minimax regret</italic> approach (<inline-formula id="IEq76"><alternatives><tex-math id="M169">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M170"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq76.gif"/></alternatives></inline-formula>) improves relapse risk prediction over the current method (<inline-formula id="IEq77"><alternatives><tex-math id="M171">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M172"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq77.gif"/></alternatives></inline-formula>). <inline-formula id="IEq78"><alternatives><tex-math id="M173">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M174"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq78.gif"/></alternatives></inline-formula> corrects for variation in strength of evidence in MRD-tests when predicting leukaemia relapse. Moreover, non-linear modeling of <inline-formula id="IEq79"><alternatives><tex-math id="M175">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M176"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq79.gif"/></alternatives></inline-formula> hazard function uncovers the critical range of MRD wherein the risk of leukaemia relapse accelerates. Because the true hazard function curve is steeper and operates at a lower range of MRD than previously realised based on <inline-formula id="IEq80"><alternatives><tex-math id="M177">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}$$\end{document}</tex-math><mml:math id="M178"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq80.gif"/></alternatives></inline-formula> it is important to continue developing and using increasingly sensitive (and specific) assays for detecting residual leukaemia cells.</p><p id="Par24">We acknowledge several limitations. Our analyses of the clinical data were retrospective and subject to bias. We focused on MPFC, which enumerates mostly live cells one-by-one and is distinct from other types of assays such as quantitative real time polymerase chain reaction (RT-qPCR) or next generation sequencing (NGS). We also did not analyse false-positive errors in MRD-tests, which are more likely a <italic>biological</italic> than statistical issue as many or perhaps most false-positives are caused by not knowing which leukaemia cells have the biological ability to cause relapse within an observation interval [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. In MPFC some aberrant leukaemia phenotypes may be more confidently identified as <italic>positive</italic> compared with others. Consequently, further refinement of results of MRD-testing is possible. Also, molecular tests such as NGS may increase accuracy&#x000a0;of identifying residual leukaemia cells [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. However, sampling error remains an inherent limitation for any MRD-test as does the current inability to identify leukaemia cells biologically able to cause relapse regardless of detection technology.</p><p id="Par25">We suggest our proposed metric <inline-formula id="IEq81"><alternatives><tex-math id="M179">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{worst}}}}}}\_{{{{{\rm{case}}}}}}}$$\end{document}</tex-math><mml:math id="M180"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">worst</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="normal">case</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq81.gif"/></alternatives></inline-formula> will help haematologists more accurately predict leukaemia relapse. It is possible to further improve accuracy of predicting leukaemia relapse by considering additional data beyond MRD-tests provided confounding <italic>predictive</italic> and <italic>prognostic</italic> co-variates are adjusted for and the therapy regimen is considered.</p></sec><sec sec-type="supplementary-material"><sec id="Sec7"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41375_2023_2026_MOESM1_ESM.docx"><caption><p>Supplement material</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn id="Fn1"><label>1</label><p id="Par11">Strictly speaking, the worst possible value of true MRD is always &#x02248;1 even when <inline-formula id="IEq14"><alternatives><tex-math id="M181">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{\rm{MRD}}}}}}}_{{{{{{\rm{conventional}}}}}}}=0$$\end{document}</tex-math><mml:math id="M182"><mml:msub><mml:mrow><mml:mi mathvariant="normal">MRD</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">conventional</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math><inline-graphic xlink:href="41375_2023_2026_Article_IEq14.gif"/></alternatives></inline-formula>. (The chance of true MRD &#x02248;1 might be practically zero but the probability of this unlikely event is never zero.) Defining the worst-case scenario estimate as &#x0201c;not likely (probability &#x02264; 0.05) to exceed this value&#x0201d; is more useful for comparing MRD-test results.</p></fn><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Yahui Feng, Saibing Qi, Xueou Liu, Li Zhang.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41375-023-02026-4.</p></sec><ack><title>Acknowledgements</title><p>Profs. Nick Cross (University of Southampton), Christopher Hourigan (National Institutes of Health) and Alec Morley (Flinders University) kindly reviewed the typescript. RPG acknowledges support from the National Institute of Health Research (NIHR). JC acknowledges support from the Institute of Hematology, Chinese Academy of Medical Sciences (IHCAMS).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>JC and RPG conceived the study. XZ co-led the CCCG-ALL-2015 study, assisted by LZ and JW. HW led the team that performed MRD-testing. XL and QS compiled and curated the data, assisted by YH, WY, TW and ZS. JC developed the alternative MRD metric. YF, SQ, XL, YH, XG and WZ did the computation and developed the graphs and tables. JC and RPG prepared the typescript. All the authors reviewed the typescript, take responsibility for the content and agreed to submit for publication.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Supported, in part, by grants from the Ministry of Science and Technology of China (2019YFA0110803; XZ), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-001 and 2022-I2M-2-003; JC), the National Institute of Health Research (NIHR) Biomedical Research Centre (RPG) and the Ministry of Science and Technology of China (84000-51200002; RPG).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Clinical data are available upon reasonable request to the corresponding authors.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par26">RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par27">Approved by the Academic Committee (IIT-NI2020001) and Ethics Review Committee (NI2020001-EC-1) of the Institute of Hematology, Chinese Academy of Medical Sciences (IHCAMS). Subjects gave written informed consent consistent with precepts of the Helsinki Declaration.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucio</surname><given-names>P</given-names></name><name><surname>Parreira</surname><given-names>A</given-names></name><name><surname>van den Beemd</surname><given-names>MW</given-names></name><name><surname>van Lochem</surname><given-names>EG</given-names></name><name><surname>van Wering</surname><given-names>ER</given-names></name><name><surname>Baars</surname><given-names>E</given-names></name><etal/></person-group><article-title>Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL</article-title><source>Leukemia</source><year>1999</year><volume>13</volume><fpage>419</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2401279</pub-id><pub-id pub-id-type="pmid">10086733</pub-id>
</element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabert</surname><given-names>J</given-names></name><name><surname>Beillard</surname><given-names>E</given-names></name><name><surname>van der Velden</surname><given-names>VH</given-names></name><name><surname>Bi</surname><given-names>W</given-names></name><name><surname>Grimwade</surname><given-names>D</given-names></name><name><surname>Pallisgaard</surname><given-names>N</given-names></name><etal/></person-group><article-title>Standardization and quality control studies of &#x02018;real-time&#x02019; quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>2318</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2403135</pub-id><pub-id pub-id-type="pmid">14562125</pub-id>
</element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullighan</surname><given-names>CG</given-names></name><name><surname>Goorha</surname><given-names>S</given-names></name><name><surname>Radtke</surname><given-names>I</given-names></name><name><surname>Miller</surname><given-names>CB</given-names></name><name><surname>Coustan-Smith</surname><given-names>E</given-names></name><name><surname>Dalton</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia</article-title><source>Nature</source><year>2007</year><volume>446</volume><fpage>758</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/nature05690</pub-id><pub-id pub-id-type="pmid">17344859</pub-id>
</element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vardiman</surname><given-names>JW</given-names></name><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Arber</surname><given-names>DA</given-names></name><name><surname>Brunning</surname><given-names>RD</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><name><surname>Porwit</surname><given-names>A</given-names></name><etal/></person-group><article-title>The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>937</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-03-209262</pub-id><pub-id pub-id-type="pmid">19357394</pub-id>
</element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conter</surname><given-names>V</given-names></name><name><surname>Bartram</surname><given-names>CR</given-names></name><name><surname>Valsecchi</surname><given-names>MG</given-names></name><name><surname>Schrauder</surname><given-names>A</given-names></name><name><surname>Panzer-Grumayer</surname><given-names>R</given-names></name><name><surname>Moricke</surname><given-names>A</given-names></name><etal/></person-group><article-title>Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>3206</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-248146</pub-id><pub-id pub-id-type="pmid">20154213</pub-id>
</element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Bullinger</surname><given-names>L</given-names></name><name><surname>Gaidzik</surname><given-names>VI</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>ND</given-names></name><etal/></person-group><article-title>Genomic classification and prognosis in acute myeloid leukemia</article-title><source>N. Engl J Med</source><year>2016</year><volume>374</volume><fpage>2209</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1516192</pub-id><pub-id pub-id-type="pmid">27276561</pub-id>
</element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estey</surname><given-names>E</given-names></name><name><surname>Gale</surname><given-names>RP</given-names></name></person-group><article-title>How good are we at predicting the fate of someone with acute myeloid leukaemia?</article-title><source>Leukemia</source><year>2017</year><volume>31</volume><fpage>1255</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.56</pub-id><pub-id pub-id-type="pmid">28303892</pub-id>
</element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hourigan</surname><given-names>CS</given-names></name><name><surname>Gale</surname><given-names>RP</given-names></name><name><surname>Gormley</surname><given-names>NJ</given-names></name><name><surname>Ossenkoppele</surname><given-names>GJ</given-names></name><name><surname>Walter</surname><given-names>RB</given-names></name></person-group><article-title>Measurable residual disease testing in acute myeloid leukaemia</article-title><source>Leukemia</source><year>2017</year><volume>31</volume><fpage>1482</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.113</pub-id><pub-id pub-id-type="pmid">28386105</pub-id>
</element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceppi</surname><given-names>F</given-names></name><name><surname>Rizzati</surname><given-names>F</given-names></name><name><surname>Colombini</surname><given-names>A</given-names></name><name><surname>Conter</surname><given-names>V</given-names></name><name><surname>Cazzaniga</surname><given-names>G</given-names></name></person-group><article-title>Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia</article-title><source>Expert Rev Hematol</source><year>2021</year><volume>14</volume><fpage>795</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1080/17474086.2021.1967137</pub-id><pub-id pub-id-type="pmid">34374613</pub-id>
</element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dohner</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>AH</given-names></name><name><surname>Appelbaum</surname><given-names>FR</given-names></name><name><surname>Craddock</surname><given-names>C</given-names></name><name><surname>DiNardo</surname><given-names>CD</given-names></name><name><surname>Dombret</surname><given-names>H</given-names></name><etal/></person-group><article-title>Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN</article-title><source>Blood</source><year>2022</year><volume>140</volume><fpage>1345</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1182/blood.2022016867</pub-id><pub-id pub-id-type="pmid">35797463</pub-id>
</element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terwijn</surname><given-names>M</given-names></name><name><surname>van Putten</surname><given-names>WL</given-names></name><name><surname>Kelder</surname><given-names>A</given-names></name><name><surname>van der Velden</surname><given-names>VH</given-names></name><name><surname>Brooimans</surname><given-names>RA</given-names></name><name><surname>Pabst</surname><given-names>T</given-names></name><etal/></person-group><article-title>High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3889</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.45.9628</pub-id><pub-id pub-id-type="pmid">24062400</pub-id>
</element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>SD</given-names></name><name><surname>Virgo</surname><given-names>P</given-names></name><name><surname>Couzens</surname><given-names>S</given-names></name><name><surname>Grimwade</surname><given-names>D</given-names></name><name><surname>Russell</surname><given-names>N</given-names></name><name><surname>Hills</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>4123</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.49.1753</pub-id><pub-id pub-id-type="pmid">24062403</pub-id>
</element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Walter</surname><given-names>RB</given-names></name><name><surname>Pagel</surname><given-names>JM</given-names></name><name><surname>Becker</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>1258</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.3518</pub-id><pub-id pub-id-type="pmid">25732155</pub-id>
</element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Othus</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>BL</given-names></name><name><surname>Stirewalt</surname><given-names>DL</given-names></name><name><surname>Estey</surname><given-names>EH</given-names></name><name><surname>Petersdorf</surname><given-names>SH</given-names></name><name><surname>Appelbaum</surname><given-names>FR</given-names></name><etal/></person-group><article-title>Effect of measurable (&#x02018;minimal&#x02019;) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia</article-title><source>Leukemia</source><year>2016</year><volume>30</volume><fpage>2080</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/leu.2016.120</pub-id><pub-id pub-id-type="pmid">27133827</pub-id>
</element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>DA</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Higley</surname><given-names>H</given-names></name><name><surname>Mukundan</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Reaman</surname><given-names>GH</given-names></name><etal/></person-group><article-title>Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis</article-title><source>JAMA Oncol</source><year>2017</year><volume>3</volume><fpage>e170580</fpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.0580</pub-id><pub-id pub-id-type="pmid">28494052</pub-id>
</element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dillon</surname><given-names>LW</given-names></name><name><surname>Gui</surname><given-names>G</given-names></name><name><surname>Page</surname><given-names>KM</given-names></name><name><surname>Ravindra</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>ZC</given-names></name><name><surname>Andrew</surname><given-names>G</given-names></name><etal/></person-group><article-title>DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant</article-title><source>JAMA</source><year>2023</year><volume>329</volume><fpage>745</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.1363</pub-id><pub-id pub-id-type="pmid">36881031</pub-id>
</element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>M</given-names></name><name><surname>Kiss</surname><given-names>C</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Riccheri</surname><given-names>C</given-names></name><name><surname>Kowalczyk</surname><given-names>J</given-names></name><name><surname>Felice</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Childhood acute lymphoblastic leukemia: results of the randomized acute lymphoblastic leukemia Intercontinental-Berlin-Frankfurt-Munster 2009 Trial</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><fpage>3499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01760</pub-id><pub-id pub-id-type="pmid">37141547</pub-id>
</element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beillard</surname><given-names>E</given-names></name><name><surname>Pallisgaard</surname><given-names>N</given-names></name><name><surname>van der Velden</surname><given-names>VH</given-names></name><name><surname>Bi</surname><given-names>W</given-names></name><name><surname>Dee</surname><given-names>R</given-names></name><name><surname>van der Schoot</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using &#x02018;real-time&#x02019; quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>2474</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2403136</pub-id><pub-id pub-id-type="pmid">14562124</pub-id>
</element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Velden</surname><given-names>VH</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Cazzaniga</surname><given-names>G</given-names></name><name><surname>Szczepanski</surname><given-names>T</given-names></name><name><surname>Gabert</surname><given-names>J</given-names></name><name><surname>van Dongen</surname><given-names>JJ</given-names></name></person-group><article-title>Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects</article-title><source>Leukemia</source><year>2003</year><volume>17</volume><fpage>1013</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2402922</pub-id><pub-id pub-id-type="pmid">12764363</pub-id>
</element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loken</surname><given-names>MR</given-names></name><name><surname>Alonzo</surname><given-names>TA</given-names></name><name><surname>Pardo</surname><given-names>L</given-names></name><name><surname>Gerbing</surname><given-names>RB</given-names></name><name><surname>Raimondi</surname><given-names>SC</given-names></name><name><surname>Hirsch</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children&#x02019;s Oncology Group</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>1581</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-02-408336</pub-id><pub-id pub-id-type="pmid">22649108</pub-id>
</element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalina</surname><given-names>T</given-names></name><name><surname>Flores-Montero</surname><given-names>J</given-names></name><name><surname>van der Velden</surname><given-names>VH</given-names></name><name><surname>Martin-Ayuso</surname><given-names>M</given-names></name><name><surname>Bottcher</surname><given-names>S</given-names></name><name><surname>Ritgen</surname><given-names>M</given-names></name><etal/></person-group><article-title>EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols</article-title><source>Leukemia</source><year>2012</year><volume>26</volume><fpage>1986</fpage><lpage>2010</lpage><pub-id pub-id-type="doi">10.1038/leu.2012.122</pub-id><pub-id pub-id-type="pmid">22948490</pub-id>
</element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dongen</surname><given-names>JJ</given-names></name><name><surname>Lhermitte</surname><given-names>L</given-names></name><name><surname>Bottcher</surname><given-names>S</given-names></name><name><surname>Almeida</surname><given-names>J</given-names></name><name><surname>van der Velden</surname><given-names>VH</given-names></name><name><surname>Flores-Montero</surname><given-names>J</given-names></name><etal/></person-group><article-title>EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes</article-title><source>Leukemia</source><year>2012</year><volume>26</volume><fpage>1908</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/leu.2012.120</pub-id><pub-id pub-id-type="pmid">22552007</pub-id>
</element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimwade</surname><given-names>D</given-names></name><name><surname>Freeman</surname><given-names>SD</given-names></name></person-group><article-title>Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for &#x0201c;prime time&#x0201d;?</article-title><source>Blood</source><year>2014</year><volume>124</volume><fpage>3345</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-05-577593</pub-id><pub-id pub-id-type="pmid">25049280</pub-id>
</element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladetto</surname><given-names>M</given-names></name><name><surname>Bruggemann</surname><given-names>M</given-names></name><name><surname>Monitillo</surname><given-names>L</given-names></name><name><surname>Ferrero</surname><given-names>S</given-names></name><name><surname>Pepin</surname><given-names>F</given-names></name><name><surname>Drandi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders</article-title><source>Leukemia</source><year>2014</year><volume>28</volume><fpage>1299</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.375</pub-id><pub-id pub-id-type="pmid">24342950</pub-id>
</element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulsipher</surname><given-names>MA</given-names></name><name><surname>Carlson</surname><given-names>C</given-names></name><name><surname>Langholz</surname><given-names>B</given-names></name><name><surname>Wall</surname><given-names>DA</given-names></name><name><surname>Schultz</surname><given-names>KR</given-names></name><name><surname>Bunin</surname><given-names>N</given-names></name><etal/></person-group><article-title>IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients</article-title><source>Blood</source><year>2015</year><volume>125</volume><fpage>3501</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-12-615757</pub-id><pub-id pub-id-type="pmid">25862561</pub-id>
</element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saygin</surname><given-names>C</given-names></name><name><surname>Cannova</surname><given-names>J</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Muffly</surname><given-names>L</given-names></name></person-group><article-title>Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients</article-title><source>Haematologica</source><year>2022</year><volume>107</volume><fpage>2783</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.3324/haematol.2022.280638</pub-id><pub-id pub-id-type="pmid">36453516</pub-id>
</element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roschewski</surname><given-names>M</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Mailankody</surname><given-names>S</given-names></name><name><surname>Korde</surname><given-names>N</given-names></name><name><surname>Landgren</surname><given-names>O</given-names></name></person-group><article-title>Minimal residual disease: what are the minimum requirements?</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><fpage>475</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.52.1955</pub-id><pub-id pub-id-type="pmid">24419126</pub-id>
</element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuurhuis</surname><given-names>GJ</given-names></name><name><surname>Heuser</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>Bene</surname><given-names>MC</given-names></name><name><surname>Buccisano</surname><given-names>F</given-names></name><name><surname>Cloos</surname><given-names>J</given-names></name><etal/></person-group><article-title>Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party</article-title><source>Blood</source><year>2018</year><volume>131</volume><fpage>1275</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-09-801498</pub-id><pub-id pub-id-type="pmid">29330221</pub-id>
</element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paiva</surname><given-names>B</given-names></name><name><surname>Puig</surname><given-names>N</given-names></name><name><surname>Cedena</surname><given-names>MT</given-names></name><name><surname>Rosinol</surname><given-names>L</given-names></name><name><surname>Cordon</surname><given-names>L</given-names></name><name><surname>Vidriales</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Measurable residual disease by next-generation flow cytometry in multiple myeloma</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><fpage>784</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.01231</pub-id><pub-id pub-id-type="pmid">31770060</pub-id>
</element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buccisano</surname><given-names>F</given-names></name><name><surname>Palmieri</surname><given-names>R</given-names></name><name><surname>Piciocchi</surname><given-names>A</given-names></name><name><surname>Arena</surname><given-names>V</given-names></name><name><surname>Maurillo</surname><given-names>L</given-names></name><name><surname>Del Principe</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial</article-title><source>Haematologica</source><year>2022</year><volume>107</volume><fpage>2823</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3324/haematol.2021.279777</pub-id><pub-id pub-id-type="pmid">35295076</pub-id>
</element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeha</surname><given-names>S</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Sandlund</surname><given-names>JT</given-names></name><name><surname>Coustan-Smith</surname><given-names>E</given-names></name><etal/></person-group><article-title>Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><fpage>3377</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.01692</pub-id><pub-id pub-id-type="pmid">31657981</pub-id>
</element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><fpage>1322</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00328-4</pub-id><pub-id pub-id-type="pmid">34329606</pub-id>
</element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theunissen</surname><given-names>P</given-names></name><name><surname>Mejstrikova</surname><given-names>E</given-names></name><name><surname>Sedek</surname><given-names>L</given-names></name><name><surname>van der Sluijs-Gelling</surname><given-names>AJ</given-names></name><name><surname>Gaipa</surname><given-names>G</given-names></name><name><surname>Bartels</surname><given-names>M</given-names></name><etal/></person-group><article-title>Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia</article-title><source>Blood</source><year>2017</year><volume>129</volume><fpage>347</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-07-726307</pub-id><pub-id pub-id-type="pmid">27903527</pub-id>
</element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modvig</surname><given-names>S</given-names></name><name><surname>Hallbook</surname><given-names>H</given-names></name><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Siitonen</surname><given-names>S</given-names></name><name><surname>Rosthoj</surname><given-names>S</given-names></name><name><surname>Tierens</surname><given-names>A</given-names></name><etal/></person-group><article-title>Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting</article-title><source>Leukemia</source><year>2021</year><volume>35</volume><fpage>1894</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-01100-5</pub-id><pub-id pub-id-type="pmid">33318611</pub-id>
</element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis. 3rd ed. Boca Raton, FL: Chapman and Hall/CRC; 2013.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>HA</given-names></name></person-group><article-title>A behavioral model of rational choice</article-title><source>Q J Econ</source><year>1955</year><volume>69</volume><fpage>99</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.2307/1884852</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>LJ</given-names></name></person-group><article-title>The theory of statistical decision</article-title><source>J Am Stat Assoc</source><year>1951</year><volume>46</volume><fpage>55</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1080/01621459.1951.10500768</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pencina</surname><given-names>MJ</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name></person-group><article-title>Evaluating discrimination of risk prediction models: the C statistic</article-title><source>JAMA</source><year>2015</year><volume>314</volume><fpage>1063</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.11082</pub-id><pub-id pub-id-type="pmid">26348755</pub-id>
</element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efron</surname><given-names>B</given-names></name></person-group><article-title>Bootstrap methods: another look at the jackknife</article-title><source>Ann Stat</source><year>1979</year><volume>7</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1214/aos/1176344552</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>S</given-names></name><name><surname>Gelatt</surname><given-names>CD</given-names><suffix>Jr</suffix></name><name><surname>Vecchi</surname><given-names>MP</given-names></name></person-group><article-title>Optimization by simulated annealing</article-title><source>Science</source><year>1983</year><volume>220</volume><fpage>671</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1126/science.220.4598.671</pub-id><pub-id pub-id-type="pmid">17813860</pub-id>
</element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Green PJ, Silverman BW. Nonparametric regression and generalized linear models: a roughness penalty approach. London: Chapman &#x00026; Hall; 1994.</mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>QV</given-names></name><name><surname>Gooley</surname><given-names>TA</given-names></name></person-group><article-title>Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians</article-title><source>Bone Marrow Transpl</source><year>2020</year><volume>55</volume><fpage>675</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/s41409-019-0679-x</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Chen J, Gale RP, Feng Y, Hu Y, Qi S, Liu X, et al. Are haematopoietic stem cell transplants stem cell transplants, is there a threshold dose of CD34-positive cells and how many are needed for rapid posttransplant granulocyte recovery? Leukemia. 2023. 10.1038/s41375-023-01973-2.</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Mercer</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>MM</given-names></name></person-group><article-title>Common leukemia- and lymphoma-associated genetic aberrations in healthy individuals</article-title><source>J Mol Diagn</source><year>2011</year><volume>13</volume><fpage>213</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2010.10.009</pub-id><pub-id pub-id-type="pmid">21354057</pub-id>
</element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farina</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Bellotti</surname><given-names>D</given-names></name><name><surname>Marchina</surname><given-names>E</given-names></name><name><surname>Gale</surname><given-names>RP</given-names></name></person-group><article-title>Is having clonal cytogenetic abnormalities the same as having leukaemia</article-title><source>Acta Haematol</source><year>2016</year><volume>135</volume><fpage>39</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1159/000437202</pub-id><pub-id pub-id-type="pmid">26376174</pub-id>
</element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AL</given-names></name><name><surname>Challen</surname><given-names>GA</given-names></name><name><surname>Birmann</surname><given-names>BM</given-names></name><name><surname>Druley</surname><given-names>TE</given-names></name></person-group><article-title>Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>12484</fpage><pub-id pub-id-type="doi">10.1038/ncomms12484</pub-id><pub-id pub-id-type="pmid">27546487</pub-id>
</element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><etal/></person-group><article-title>Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis</article-title><source>Nat Cell Biol</source><year>2022</year><volume>24</volume><fpage>242</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/s41556-021-00814-7</pub-id><pub-id pub-id-type="pmid">35145224</pub-id>
</element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group><article-title>A class of K-sample tests for comparing the cumulative incidence of a competing risk</article-title><source>Ann Stat</source><year>1988</year><volume>16</volume><fpage>1141</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1214/aos/1176350951</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>JP</given-names></name><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group><article-title>A proportional hazards model for the subdistribution of a competing risk</article-title><source>J Am Stat Assoc</source><year>1999</year><volume>94</volume><fpage>496</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1080/01621459.1999.10474144</pub-id></element-citation></ref></ref-list></back></article>
